DE69934967D1 - Verfahren zur verminderung der immunogenität von proteinen - Google Patents

Verfahren zur verminderung der immunogenität von proteinen

Info

Publication number
DE69934967D1
DE69934967D1 DE69934967T DE69934967T DE69934967D1 DE 69934967 D1 DE69934967 D1 DE 69934967D1 DE 69934967 T DE69934967 T DE 69934967T DE 69934967 T DE69934967 T DE 69934967T DE 69934967 D1 DE69934967 D1 DE 69934967D1
Authority
DE
Germany
Prior art keywords
epitopes
proteins
humans
self
reducing immunogenicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69934967T
Other languages
English (en)
Other versions
DE69934967T2 (de
Inventor
Francis Joseph Carr
Fiona Suzanne Adair
Anita Anne Hamilton
Graham Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Biovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9826925.1A external-priority patent/GB9826925D0/en
Priority claimed from GBGB9902139.6A external-priority patent/GB9902139D0/en
Application filed by Biovation Ltd filed Critical Biovation Ltd
Application granted granted Critical
Publication of DE69934967D1 publication Critical patent/DE69934967D1/de
Publication of DE69934967T2 publication Critical patent/DE69934967T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6418—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals from snakes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
DE69934967T 1998-12-08 1999-12-08 Verfahren zur verminderung der immunogenität von proteinen Expired - Fee Related DE69934967T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9826925.1A GB9826925D0 (en) 1998-12-08 1998-12-08 Therapeutic non-homologous proteins
GB9826925 1998-12-08
GB9902139 1999-02-02
GBGB9902139.6A GB9902139D0 (en) 1999-02-02 1999-02-02 Therapeutic non-autologous proteins
PCT/GB1999/004119 WO2000034317A2 (en) 1998-12-08 1999-12-08 Method for reducing immunogenicity of proteins

Publications (2)

Publication Number Publication Date
DE69934967D1 true DE69934967D1 (de) 2007-03-15
DE69934967T2 DE69934967T2 (de) 2007-12-06

Family

ID=26314799

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69934967T Expired - Fee Related DE69934967T2 (de) 1998-12-08 1999-12-08 Verfahren zur verminderung der immunogenität von proteinen

Country Status (9)

Country Link
EP (1) EP1051432B1 (de)
JP (1) JP2002534959A (de)
CN (1) CN1202128C (de)
AT (1) ATE352559T1 (de)
AU (1) AU776910B2 (de)
CA (1) CA2342967A1 (de)
DE (1) DE69934967T2 (de)
ES (1) ES2278463T3 (de)
WO (1) WO2000034317A2 (de)

Families Citing this family (355)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20020068303A1 (en) * 1994-07-14 2002-06-06 Ruth Laub Antigenic polypeptide sequences of factor VIII, and fragments and/or epitopes of these sequences
US6838269B1 (en) 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6936249B1 (en) 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US7833528B2 (en) 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
CN1387538A (zh) 1999-01-15 2002-12-25 比奥根公司 针对tweak及tweak受体的拮抗剂和它们在治疗免疫性疾病中的应用
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
EP1252183B1 (de) * 1999-12-02 2006-05-24 Thromb-X N.V. Methode zur reduzierung der immunogenizität von staphylokinase durch entfernen von t-zell epitopen
AU2001278898A1 (en) * 2000-07-10 2002-01-21 Xencor Method for disigning protein libraries with altered immunogenicity
GB0018901D0 (en) * 2000-08-03 2000-09-20 Biovation Ltd Peptides presented by cells
CA2424720C (en) * 2000-10-02 2012-04-03 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6673580B2 (en) * 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7534429B2 (en) 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
MXPA03007005A (es) * 2001-02-06 2003-11-18 Merck Patent Gmbh Factor neutrofico derivado del cerebro (bdnf) humano modificado con unmunogenicidad reducida.
US20040063917A1 (en) * 2001-02-06 2004-04-01 Carr Francis J. Modified erythropoietin (epo) with reduced immunogenicity
MXPA03007004A (es) * 2001-02-06 2003-11-18 Merck Patent Gesellscahft Mit Antagonista del receptor de interleucina-1 (il-1ra) modificado con inmunogenicidad reducida.
RU2003125641A (ru) * 2001-02-06 2005-03-10 Мерк Патент ГмбХ (DE) Модифицированный колониестимулирующий гранулоцитарный фактор (g-csf) с уменьшенной иммуногенностью
CN1491231A (zh) * 2001-02-06 2004-04-21 Ĭ��ר�����޹�˾ 免疫原性减弱的经修饰角质形成细胞生长因子(kgf)
CA2437265A1 (en) * 2001-02-06 2002-08-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified leptin with reduced immunogenicity
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
KR100899970B1 (ko) 2001-02-19 2009-05-28 메르크 파텐트 게엠베하 Ｔ-세포 에피토프의 동정 방법 및 감소된 면역원성을 갖는분자의 제조를 위한 용도
US7189830B2 (en) * 2001-02-19 2007-03-13 Merck Patent Gmbh Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
US7132511B2 (en) * 2001-02-19 2006-11-07 Merck Patent Gmbh Modified anti-EGFR antibodies with reduced immunogenicity
MXPA03008032A (es) 2001-03-08 2003-12-04 Merck Patent Gmbh Factor de estimulacion de colonias de granulocitos- macrofagos modificado con inmunogenicidad reducida.
KR20030084992A (ko) * 2001-03-15 2003-11-01 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질 인터페론 베타
KR20030085007A (ko) * 2001-03-20 2003-11-01 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 변형된 인슐린
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7045605B2 (en) 2001-06-01 2006-05-16 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7087724B2 (en) 2001-06-26 2006-08-08 Agen Biomedical Ltd Carrier molecules
EP1414471B1 (de) 2001-07-17 2012-06-13 Research Development Foundation Therapeutische Mittel mit pro-apoptotischen Proteinen
CA2459138A1 (en) * 2001-09-04 2003-03-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified human growth hormone
HUP0401534A3 (en) * 2001-09-04 2006-01-30 Merck Patent Gmbh Modified factor ix
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2466592A1 (en) * 2001-11-12 2003-05-22 Koen Hellendoorn Modified anti-tnf alpha antibody
US20030100016A1 (en) * 2001-11-23 2003-05-29 George Jackowski Complement C3 precursor biopolymer markers predictive of Alzheimers disease
WO2003086311A2 (en) 2002-04-09 2003-10-23 Biogen, Inc. Methods for treating tweak-related conditions
BR0308860A (pt) * 2002-04-18 2005-01-04 Merck Patent Gmbh Fator viii modificado
EP2298278B1 (de) 2002-06-07 2015-11-11 Dyax Corp. Verhinderung und Reduzierung von Blutverlust und Entzündungsreaktion
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
KR20050010898A (ko) * 2002-06-11 2005-01-28 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질 브리오딘 1
DE60304040T2 (de) * 2002-06-11 2006-09-28 Merck Patent Gmbh Methode zur identifizierung und eliminierung von t-zell epitopen
DE10233047A1 (de) * 2002-07-19 2004-02-26 Amaxa Gmbh Verfahren zur Herstellung eines künstlichen Polypeptids und nach diesem Verfahren hergestelltes künstliches Protein
US20040018568A1 (en) * 2002-07-23 2004-01-29 Subhashis Banerjee Methods for detecting deantigenized T cell epitopes and uses thereof
US20040121953A1 (en) * 2002-08-09 2004-06-24 Chirino Arthur J. Thrombopoiesis-stimulating proteins having reduced immunogenicity
CN1675242A (zh) * 2002-08-09 2005-09-28 默克专利有限公司 ***中的t－细胞表位
ES2709103T3 (es) 2002-08-28 2019-04-15 Dyax Corp Métodos para conservar órganos y tejidos
AU2003298650B2 (en) 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
US7169904B2 (en) 2002-12-17 2007-01-30 Emd Lexigen Research Center Corp. Immunocytokine sequences and uses thereof
US7488475B2 (en) 2003-01-21 2009-02-10 Arius Research, Inc. Antibody therapy of tumors
PT2248899E (pt) 2003-03-19 2015-09-23 Biogen Ma Inc Proteína de ligação do receptor nogo
JP2007530438A (ja) * 2003-03-28 2007-11-01 ジェフ ヒマワン， 免疫原性を低下させた抗ｃｒ１抗体及び組成物並びにそれに基づく治療法
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
NZ546173A (en) 2003-10-16 2009-04-30 Micromet Ag Multispecific deimmunized CD3-binders
CN1898267B (zh) 2003-11-01 2012-05-23 默克专利股份有限公司 修饰的抗cd52抗体
WO2005044855A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
CA2544368C (en) 2003-11-04 2014-04-01 Chiron Corporation Methods of therapy for b cell-related cancers
CA2544852A1 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
PT1682177E (pt) 2003-11-04 2010-11-29 Xoma Technology Lt Utilização de anticorpos antagonistas anti-cd40 para o tratamento da leucemia linfocítica crónica
PT1682178E (pt) 2003-11-04 2010-10-21 Novartis Vaccines & Diagnostic Métodos de terapêutica para cancros que expressam o antigénio cd40
EP1697415A1 (de) 2003-11-12 2006-09-06 Biogen Idec MA Inc. Polypeptidvarianten, die an den neonatal-fc-receptor (fcrn) binden, dimere fc-bindende proteine und damit in zusammenhang stehende verfahren
WO2005056759A2 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US20060122783A1 (en) * 2004-08-24 2006-06-08 Ishikawa Muriel Y System and method for heightening a humoral immune response
WO2005070967A2 (en) 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
CN1954073B (zh) * 2004-03-19 2013-01-16 默克专利股份有限公司 被修饰Bouganin蛋白、细胞毒素及其方法和用途
PT1737961E (pt) 2004-03-19 2013-08-26 Merck Patent Gmbh Proteínas buganina modificadas, citotoxinas e métodos e utilizações das mesmas
ES2395094T3 (es) 2004-06-24 2013-02-08 Biogen Idec Ma Inc. Tratamiento de afecciones que implican la desmielinización
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
WO2006029094A2 (en) * 2004-09-02 2006-03-16 Xencor, Inc. Erythropoietin derivatives with altered immunogenicity
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP2845865A1 (de) 2004-11-12 2015-03-11 Xencor Inc. FC-Varianten mit Veränderter Bindung zu FCRN
US20080206239A1 (en) * 2005-02-03 2008-08-28 Antitope Limited Human Antibodies And Proteins
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
AU2006227377B2 (en) * 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
EP1863531A1 (de) 2005-03-19 2007-12-12 Medical Research Council Verbesserungen der behandlung und prävention von virusinfektionen
EP1868647A4 (de) 2005-03-24 2009-04-01 Millennium Pharm Inc Ov064-bindende antikörper und verfahren zu ihrer verwendung
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
CA2605723A1 (en) 2005-04-25 2006-11-02 Pfizer Inc. Antibodies to myostatin
GEP20115226B (en) 2005-04-26 2011-06-10 Pfizer P-cadherin antibodies
EP1885388B1 (de) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Behandlung und beurteilung von entzündlichen erkrankungen
PL1889065T3 (pl) 2005-05-18 2013-12-31 Novartis Ag Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
LT2460831T (lt) 2005-05-27 2016-12-12 Biogen Ma Inc. Tweak rišantys antikūnai
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP2238986A3 (de) 2005-07-08 2010-11-03 Biogen Idec MA Inc. Sp35-Antikörper und Verwendungen dafür
JP2009500390A (ja) * 2005-07-08 2009-01-08 ファイザー・リミテッド 新規ＭＡｄＣＡＭ抗体
WO2007008951A1 (en) * 2005-07-12 2007-01-18 Codon Devices, Inc. Compositions and methods for design of non-immunogenic proteins
US7494648B2 (en) 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US7452978B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7456258B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7452979B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7456259B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
JP2009502195A (ja) * 2005-08-04 2009-01-29 セントカー・インコーポレーテツド 抗ＴＮＦα抗体および使用方法
UA94060C2 (ru) 2005-09-07 2011-04-11 Эмджен Фримонт Инк. Моноклональное антитело, которое специфически связывает alk-1
AU2006301492B2 (en) 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
EP1959979A4 (de) 2005-11-04 2010-01-27 Biogen Idec Inc Verfahren zur förderung des axonen-wachstums und des überlebens dopaminergischer neuronen
CA2631181A1 (en) 2005-12-02 2007-06-07 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
US8394926B2 (en) 2005-12-21 2013-03-12 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA
ES2384055T3 (es) 2005-12-30 2012-06-28 Merck Patent Gmbh Variantes de la interleucina-12p40 con estabilidad mejorada
PT2270050E (pt) 2005-12-30 2013-09-12 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
DK2463305T3 (en) 2006-01-12 2016-08-29 Alexion Pharma Inc Antibodies to OX-2 / CD200 and uses thereof
BRPI0707276B1 (pt) 2006-01-27 2021-08-31 Biogen Ma Inc Polipeptídeo de fusão antagonista de receptor nogo
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
WO2007124299A2 (en) 2006-04-21 2007-11-01 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
KR101557603B1 (ko) 2006-06-08 2015-10-06 추가이 세이야쿠 가부시키가이샤 염증성 질환의 예방 또는 치료제
ES2523640T3 (es) 2006-06-21 2014-11-28 Musc Foundation For Research Development Direccionamiento del factor H del complemento para el tratamiento de enfermedades
WO2008019290A2 (en) 2006-08-04 2008-02-14 Astrazeneca Ab Human antibodies to erbb 2
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
BRPI0715794A2 (pt) 2006-08-17 2013-07-23 Hoffmann La Roche conjugado de anticorpo contra ccr5 e peptÍdeo antifusogÊnico
WO2008042261A2 (en) 2006-09-28 2008-04-10 Elusys Therapeutics, Inc. Anti-anthrax antibody, formulations thereof, and methods of use
RU2009111138A (ru) 2006-10-12 2010-11-20 Вайет (Us) Способы и композиции с уменьшенной опалесценцией
CA2666317C (en) 2006-11-03 2013-08-06 Wyeth Glycolysis-inhibiting substances in cell culture
RU2009122233A (ru) 2006-11-13 2010-12-20 Ф.Хоффманн-Ля Рош Аг (Ch) Антитела, модифицирующие раковые заболевания
MX2009005398A (es) 2006-11-21 2009-08-20 Kalobios Pharmaceuticals Inc Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
SG177954A1 (en) 2007-01-05 2012-02-28 Univ Zuerich Method of providing disease-specific binding molecules and targets
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
SG177966A1 (en) 2007-01-09 2012-02-28 Biogen Idec Inc Sp35 antibodies and uses thereof
PT3199180T (pt) 2007-03-08 2022-04-01 Univ Monash Anticorpos epha3 para o tratamento de tumores sólidos
MX2009010765A (es) 2007-04-02 2009-10-26 Amgen Fremont Inc Anticuerpos anti-ige.
JP2010530895A (ja) 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素
JP5341889B2 (ja) 2007-07-17 2013-11-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作された抗αＶインテグリンハイブリッド抗体
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
WO2009023185A1 (en) 2007-08-13 2009-02-19 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
EP3689912A1 (de) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstitution in cdr
ES2566957T3 (es) 2007-09-26 2016-04-18 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
EP2740490A1 (de) 2007-10-03 2014-06-11 Cornell University Behandlung von proliferativen Erkrankungen mit PSMA-Antikörpern
KR101280704B1 (ko) 2007-10-12 2013-07-01 에프. 호프만-라 로슈 아게 다수의 핵산으로부터의 단백질 발현
EP2236604B1 (de) 2007-12-05 2016-07-06 Chugai Seiyaku Kabushiki Kaisha Anti-nr10-antikörper und verwendung davon
BRPI0821145B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido
ES2532483T3 (es) 2007-12-15 2015-03-27 F. Hoffmann-La Roche Ag Ensayo de distinción
EP3575317A1 (de) 2007-12-26 2019-12-04 Xencor, Inc. Fc-varianten mit veränderter bindung zu fcrn
ATE555131T1 (de) 2008-01-15 2012-05-15 Kalobios Pharmaceuticals Inc Verfahren zur behandlung von erkrankungen mit knochenabbau unter verwendung eines gm-csf- antagonisten
JP2011517314A (ja) 2008-02-14 2011-06-02 ブリストル−マイヤーズ スクイブ カンパニー Ｅｇｆｒに結合する操作されたタンパク質に基づく標的化された治療薬
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
TWI564021B (zh) 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
WO2009131702A2 (en) 2008-04-25 2009-10-29 Dyax Corp. Antibodies against fcrn and use thereof
EP2799448A1 (de) 2008-05-22 2014-11-05 Bristol-Myers Squibb Company Polyvalente Proteine mit Fibronectin-Gerüstdomänen
WO2010005570A2 (en) 2008-07-09 2010-01-14 Biogen Idec Ma Inc. Compositions comprising antibodies to lingo or fragments thereof
JP2012504939A (ja) 2008-09-23 2012-03-01 ワイス・エルエルシー 架橋結合タンパク質による活性化シグナルの産生を予測するための方法
WO2010045315A1 (en) 2008-10-14 2010-04-22 Dyax Corp. Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
AU2009314311B2 (en) 2008-10-29 2013-01-10 Ablynx N.V. Methods for purification of single domain antigen binding molecules
BR122018013284B1 (pt) 2008-10-29 2022-03-03 Ablynx N.V Formulações de moléculas de ligação ao antígeno de domínio único, seu método de formulação e seu uso, kit ou artigo de fabricação, bem como método para preparar uma formulação reconstituída contendo uma molécula de sdab
ES2940466T3 (es) 2008-11-10 2023-05-08 Alexion Pharma Inc Métodos y composiciones para tratar trastornos asociados al complemento
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
EP2949666B1 (de) 2008-12-19 2018-12-19 Biogen International Neuroscience GmbH Menschliche anti-alpha-synuclein-antikörper
AU2009334498A1 (en) 2008-12-31 2011-07-21 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
MX362028B (es) 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
WO2010093814A1 (en) 2009-02-11 2010-08-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a gm-csf antagonist
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
NZ594950A (en) 2009-03-06 2013-06-28 Kalobios Pharmaceuticals Inc Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
JP2012521216A (ja) 2009-03-24 2012-09-13 テバ バイオファーマスーティカルズ ユーエスエー，インコーポレーテッド Ｌｉｇｈｔに対するヒト化抗体およびその使用
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
KR101537840B1 (ko) 2009-05-13 2015-07-22 젠자임 코포레이션 항-인간 ｃｄ52 면역글루불린
ME01699B (me) 2009-07-02 2014-09-20 Musc Found For Res Dev Metode za stimulaciju regeneracije jetre
EP2448966B1 (de) 2009-07-03 2018-11-14 Avipep Pty Ltd Immunkonjugate und verfahren zu ihrer herstellung
WO2011004899A1 (en) 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
CA2766861A1 (en) 2009-07-09 2011-01-13 F. Hoffmann-La Roche Ag In vivo tumor vasculature imaging
CA2766839A1 (en) 2009-07-30 2011-02-03 F. Hoffmann-La Roche Ag Enzymatic antibody processing
WO2011026640A1 (en) 2009-09-07 2011-03-10 F. Hoffmann-La Roche Ag Es-ms of glycopeptides for analysis of glycosylation
MX366890B (es) 2009-10-23 2019-07-30 Millennium Pharm Inc Moléculas de anticuerpo anti - gcc y composiciones y métodos relacionados.
MX2012005151A (es) 2009-11-05 2012-08-23 Federico Ii University Of Naples Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
EP2496257A4 (de) 2009-11-05 2013-02-27 Cephalon Australia Pty Ltd Behandlung von krebs mit mutierten kras- oder braf-genen
WO2011057250A1 (en) 2009-11-09 2011-05-12 Alexion Pharmaceuticals, Inc. Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
AU2010336029B2 (en) 2009-12-23 2011-10-13 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
RS62853B1 (sr) 2010-01-06 2022-02-28 Takeda Pharmaceuticals Co Proteini koji vezuju kalikrein plazme
JP6012473B2 (ja) 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
SG185383A1 (en) 2010-04-30 2012-12-28 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
MX2012013233A (es) 2010-05-14 2013-05-20 Univ Colorado Regents Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
KR20130036276A (ko) 2010-06-22 2013-04-11 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 보체 결합 3의 C3d 조각에 대한 항체들
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
AU2011277983C1 (en) 2010-07-16 2016-09-29 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
MX341309B (es) 2010-07-20 2016-08-12 Cephalon Australia Pty Ltd Anticuerpos especificos del heterodimero de anti-il-23.
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
EP2420250A1 (de) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4-Antikörper
SG10201506782XA (en) 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
CN106620693A (zh) 2010-09-03 2017-05-10 艾伯维施特姆森特克斯有限责任公司 新型调节剂及使用方法
WO2012045671A1 (en) 2010-10-05 2012-04-12 F. Hoffmann-La Roche Ag Antibodies against human tweak and uses thereof
SG10201509499RA (en) 2010-11-19 2015-12-30 Eisai R&D Man Co Ltd Neutralizing anti-ccl20 antibodies
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
EP2471543A1 (de) 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Toleranzinduktion oder Immunsuppression zur Verhinderung von insbesondere Transplantat-Wirt-Reaktion (GvHD) durch kurzzeitige Vorinkubation von transplantierten Zellsuspensionen, Geweben oder Organen, die mit Liganden zu Zelloberflächenmolekülen beschichtet sind
RU2592672C9 (ru) 2010-12-08 2016-11-27 СтемСентРкс, Инк. Новые модуляторы и способы их применения
EP3628689A1 (de) 2010-12-17 2020-04-01 Neurimmune Holding AG Humane anti-sod1 antikörper
PT2654790T (pt) 2010-12-22 2019-05-16 Teva Pharmaceuticals Australia Pty Ltd Anticorpo modificado com semivida melhorada
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
US9447187B2 (en) 2011-02-03 2016-09-20 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
LT2672994T (lt) 2011-02-11 2018-07-25 Merck Patent Gmbh Anti-alfa-v integrino antikūnas, skirtas prostatos vėžio gydymui
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
WO2012122590A1 (en) 2011-03-14 2012-09-20 Cellmid Limited Antibody recognizing n-domain of midkine
KR20140018299A (ko) 2011-03-30 2014-02-12 아블린쓰 엔.브이. Ｔｎｆ-알파에 대한 단일 도메인 항체를 이용하여 면역 장애를 치료하는 방법
AU2012245073B2 (en) 2011-04-21 2016-02-11 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
CN103619353B (zh) 2011-06-02 2016-01-06 戴埃克斯有限公司 Fc受体结合蛋白
JP6058645B2 (ja) 2011-06-10 2017-01-11 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）Ｐｓｌ結合分子およびその使用
AU2012269720B2 (en) 2011-06-13 2015-01-22 Csl Limited Antibodies against G-CSFR and uses thereof
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
JP6216317B2 (ja) 2011-09-09 2017-10-18 メディミューン リミテッド 抗Ｓｉｇｌｅｃ−１５抗体およびその使用
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
EP2758438A1 (de) 2011-09-23 2014-07-30 Amgen Research (Munich) GmbH Bispezifische bindende moleküle für 5t4 und cd3
CA2850549C (en) 2011-09-30 2023-03-14 Teva Pharmaceuticals Australia Pty Ltd. Antibodies against tl1a and uses thereof
WO2013050335A1 (en) 2011-10-05 2013-04-11 F. Hoffmann-La Roche Ag Process for antibody g1 glycoform production
CA2852709A1 (en) 2011-10-28 2013-05-02 Patrys Limited Pat-lm1 epitopes and methods for using same
KR20140076602A (ko) 2011-11-08 2014-06-20 화이자 인코포레이티드 항-m-csf 항체를 사용한 염증성 장애의 치료 방법
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
JP6220344B2 (ja) 2011-11-29 2017-10-25 プロクララ バイオサイエンシーズ， インコーポレイテッド アミロイド結合剤としてのバクテリオファージのｐ３の使用
TWI640537B (zh) 2011-12-05 2018-11-11 Ｘ 染色體有限公司 ＰＤＧＦ受體β結合多肽
HUE039033T2 (hu) 2012-01-10 2018-12-28 Biogen Ma Inc Terápiás molekulák transzportjának fokozása a vér-agy gáton keresztül
SG10201801444WA (en) 2012-02-24 2018-04-27 Abbvie Stemcentrx Llc Anti sez6 antibodies and methods of use
WO2013126746A2 (en) 2012-02-24 2013-08-29 Stem Centrx, Inc. Novel modulators and methods of use
MX366864B (es) 2012-02-27 2019-07-26 Amunix Operating Inc Composiciones de conjugados de xten y métodos para realizarlas.
WO2013128027A1 (en) 2012-03-01 2013-09-06 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
KR102166083B1 (ko) 2012-03-28 2020-10-16 사노피 브라디키닌 b1 수용체 리간드에 대한 항체
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
SG11201407209YA (en) 2012-05-07 2014-12-30 Sanofi Sa Methods for preventing biofilm formation
EA030716B1 (ru) 2012-05-14 2018-09-28 Байоджен Ма Инк. Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
WO2014055515A1 (en) 2012-10-02 2014-04-10 Neurophage Pharmaceuticals, Inc. Use of p3 of bacteriophage fusion proteins as amyloid binding agents
AU2013359419B2 (en) 2012-12-10 2018-03-15 Biogen Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
CA2896824A1 (en) 2012-12-31 2014-07-03 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
CA2899960C (en) 2013-02-01 2022-05-03 Transbio Ltd Anti-cd83 antibodies and use thereof
JP6545105B2 (ja) 2013-02-07 2019-07-17 シーエスエル、リミテッド Ｉｌ−１１ｒ結合タンパク質及びその使用
CN105164159A (zh) 2013-02-22 2015-12-16 施特姆森特克斯股份有限公司 新的抗体缀合物及其用途
EA201890895A1 (ru) 2013-03-15 2019-02-28 Зинджения, Инк. Мультивалентные и моновалентные мультиспецифические комплексы и их применение
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
CN105392801A (zh) 2013-03-15 2016-03-09 比奥根Ma公司 使用抗αvβ5抗体治疗和预防急性肾损伤
WO2014150600A2 (en) 2013-03-15 2014-09-25 Angelica Therapeutics, Inc. Modified toxins
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
JP2016526044A (ja) 2013-05-28 2016-09-01 ニューロファージ ファーマシューティカルズ， インコーポレイテッド 低減された免疫原性を有する修飾されたバクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド
WO2015015448A2 (en) 2013-07-31 2015-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates
EP2832854A1 (de) 2013-08-02 2015-02-04 F. Hoffmann-La Roche AG Verfahren zur Verbesserung der rekombinanten Expression eines Polypeptids durch C-terminale Fusion mit menschlichem Neprilysin
ES2770507T3 (es) 2013-08-13 2020-07-01 Sanofi Sa Anticuerpos dirigidos contra el inhibidor de los activadores del plasminógeno de tipo 1 (PAI-1) y usos de los mismos
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
CN105848671B (zh) 2013-08-28 2019-12-13 艾伯维施特姆森特克斯有限责任公司 位点特异性抗体缀合方法和组合物
KR20160046914A (ko) 2013-08-28 2016-04-29 스템센트알엑스 인코포레이티드 신규한 ｓｅｚ6 조절물질 및 사용방법
JP6657098B2 (ja) 2013-10-21 2020-03-04 ダイアックス コーポレーション 自己免疫疾患の診断と治療
DK3074038T3 (en) 2013-11-28 2019-03-11 Csl Ltd METHOD OF TREATING DIABETIC NEPHROPATHY
US9644023B2 (en) 2013-12-09 2017-05-09 New York University Compositions and methods for phagocyte delivery of anti-staphylococcal agents
JP6553618B2 (ja) 2013-12-18 2019-07-31 シーエスエル リミティド 創傷を治療する方法
MX2016010677A (es) 2014-02-21 2017-04-10 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma.
WO2015143271A1 (en) 2014-03-21 2015-09-24 X-Body, Inc. Bi-specific antigen-binding polypeptides
EP3134439B1 (de) 2014-04-21 2018-12-26 Millennium Pharmaceuticals, Inc. Anti-psyk-antikörpermoleküle und verwendung davon für eine auf syk abzielende therapie
US11602525B2 (en) 2014-04-25 2023-03-14 Rinat Neuroscience Corp. Antibody-drug conjugates with high drug loading
JP7059003B2 (ja) 2014-05-14 2022-04-25 トラスティーズ・オブ・ダートマス・カレッジ 脱免疫化リゾスタフィン及び使用方法
US10392438B2 (en) 2014-05-16 2019-08-27 Pfizer Inc. Bispecific antibodies
CN106604741B (zh) 2014-06-12 2021-06-11 石药集团德丰有限公司 酶法制备同质的抗体-药物缀合物
WO2016016859A1 (en) 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh Constructos de anticuerpos para cdh19 y cd3
TW201609811A (zh) 2014-07-31 2016-03-16 安美基研究（慕尼黑）公司 具有增強之組織分布之雙特異性單鏈抗體構築體
RU2680238C2 (ru) 2014-08-28 2019-02-18 Пфайзер Инк. Модулирующие стабильность линкеры для использования с конъюгатами антитело-лекарственное средство
BR112017005202A2 (pt) 2014-09-16 2017-12-12 Symphogen As anticorpos anti-met e composições
SG10201902850TA (en) 2014-09-30 2019-04-29 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
NZ731491A (en) 2014-10-23 2021-12-24 Kira Biotech Pty Ltd Cd83 binding proteins and uses thereof
EP3209697A4 (de) 2014-10-23 2018-05-30 La Trobe University Fn14-bindende proteine und verwendungen davon
ES2832802T3 (es) 2014-11-21 2021-06-11 Univ Maryland Sistemas de administración dirigida del particulado específico de una estructura
EP3227341A1 (de) 2014-12-02 2017-10-11 CeMM - Forschungszentrum für Molekulare Medizin GmbH Anti-mutante calreticulin-antikörper und deren verwendung bei der diagnose und therapie von myeloiden malignomen
SG11201704427YA (en) 2014-12-03 2017-06-29 Proclara Biosciences Inc Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal
AU2015367224B2 (en) 2014-12-19 2020-12-10 Monash University IL-21 antibodies
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
EP3284480A4 (de) 2015-04-14 2018-12-05 Chugai Seiyaku Kabushiki Kaisha Pharmazeutische zusammensetzung zur prävention und/oder behandlung von atopischer dermatitis mit il-31-antagonisten als wirkstoff
HUE061730T2 (hu) 2015-04-17 2023-08-28 Amgen Res Munich Gmbh Bispecifikus antitest-konstrukciók CDH3-hoz és CD3-hoz
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
WO2017053290A1 (en) * 2015-09-23 2017-03-30 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CR20180420A (es) 2016-02-03 2018-12-05 Amgen Inc Constructos de anticuerpo biespecíficos para bcma y cd3 que se ligan a células t
SI3411404T1 (sl) 2016-02-03 2023-01-31 Amgen Research (Munich) Gmbh Konstrukti bispecifičnih protiteles PSMA in CD3, ki aktivirajo T celico
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
MX2018014876A (es) 2016-06-03 2019-05-22 Janssen Biotech Inc Dominios tipo iii de fibronectina de unión a albúmina sérica.
CN113773387B (zh) 2016-06-13 2024-06-21 天境生物科技(上海)有限公司 Pd-l1抗体及其用途
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
US20190330318A1 (en) 2016-07-25 2019-10-31 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
AU2017328383B2 (en) 2016-09-19 2022-10-27 I-Mab Biopharma (Hangzhou) Co., Ltd. Anti-GM-CSF antibodies and uses thereof
AU2017331739A1 (en) 2016-09-23 2019-03-07 Csl Limited Coagulation factor binding proteins and uses thereof
BR112019009839A2 (pt) 2016-12-21 2019-09-17 Hoffmann La Roche método para a produção enzimática de um anticorpo e anticorpo
KR102317884B1 (ko) 2016-12-21 2021-10-26 에프. 호프만-라 로슈 아게 항체의 시험관 내 당조작
KR102293106B1 (ko) 2016-12-21 2021-08-24 에프. 호프만-라 로슈 아게 항체의 시험관 내 당조작 방법
WO2018133842A1 (zh) 2017-01-20 2018-07-26 大有华夏生物医药集团有限公司 人程序性死亡受体pd-1的单克隆抗体及其片段
PE20191208A1 (es) 2017-01-24 2019-09-10 I Mab Anticuerpos anti-cd73 y usos de los mismos
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
AR111773A1 (es) 2017-05-05 2019-08-21 Amgen Inc Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración
WO2018215535A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
CN111247165B (zh) 2017-10-18 2023-11-10 Csl有限公司 人血清白蛋白变体及其应用
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
AU2018377856A1 (en) 2017-11-29 2020-05-21 Csl Limited Method of treating or preventing ischemia-reperfusion injury
EA202091422A1 (ru) 2017-12-11 2020-08-28 Эмджен Инк. Способ непрерывного производства продуктов на основе биспецифических антител
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
WO2019145475A2 (en) 2018-01-25 2019-08-01 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
FI3775909T3 (fi) 2018-03-26 2023-08-01 Glycanostics S R O Välineitä ja menetelmiä proteiinin glykoprofiloimiseksi
KR102661891B1 (ko) 2018-05-10 2024-05-23 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
WO2019218009A1 (en) 2018-05-16 2019-11-21 Csl Limited Soluble complement receptor type 1 variants and uses thereof
US20210301017A1 (en) 2018-07-30 2021-09-30 Amgen Research (Munich) Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
MA53330A (fr) 2018-08-03 2021-06-09 Amgen Inc Constructions d'anticorps pour cldn18.2 et cd3
KR102666754B1 (ko) 2018-08-21 2024-05-17 에이비엘바이오 주식회사 항-pd-l1/항-lag3 이중 특이 항체 및 이의 용도
JP2021534779A (ja) 2018-08-27 2021-12-16 アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク 抗体構築物がプレロードされた凍結保存ｎｋ細胞
US20220105176A1 (en) 2018-09-12 2022-04-07 Acm Biolabs Pte Ltd Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
SG11202105152YA (en) 2018-11-30 2021-06-29 Abl Bio Inc Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
US20220098310A1 (en) 2018-12-06 2022-03-31 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
US11028176B2 (en) 2019-02-13 2021-06-08 The Brigham And Women's Hospital, Inc. Anti-peripheral lymph node addressin antibodies and uses thereof
CN116178547A (zh) 2019-02-22 2023-05-30 武汉友芝友生物制药股份有限公司 Cd3抗原结合片段及其应用
MA55529A (fr) 2019-04-03 2022-02-09 Genzyme Corp Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
TW202045711A (zh) 2019-06-13 2020-12-16 美商安進公司 生物製品製造中基於生物量之自動灌注控制
JP2022547850A (ja) 2019-09-03 2022-11-16 バイオ － テラ ソリューションズ、リミテッド 抗ｔｉｇｉｔ免疫阻害剤及び応用
US20220306741A1 (en) 2019-09-10 2022-09-29 Amgen Inc. Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity
CA3156683A1 (en) 2019-11-13 2021-05-20 Amgen Inc. METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES
AU2020387034A1 (en) 2019-11-20 2022-06-02 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
CA3164129A1 (en) 2019-12-20 2021-06-24 Amgen Inc. Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
US11725048B2 (en) 2019-12-20 2023-08-15 Hudson Institute of Medical Research CXCL10 binding proteins and compositions thereof
EP4081554A1 (de) 2019-12-27 2022-11-02 Affimed GmbH Verfahren zur herstellung eines bispezifischen fcyriii-x-cd30-antikörper-konstrukts
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
EP4118113A1 (de) 2020-03-12 2023-01-18 Amgen Inc. Verfahren zur behandlung und prophylaxe von crs bei patienten mit einer kombination aus bispezifischen antikörpern zur bindung an cds x-krebszellen und tnfalpha- oder il-6-hemmer
AU2021240028A1 (en) 2020-03-19 2022-09-15 Amgen Inc. Antibodies against mucin 17 and uses thereof
CN115362171A (zh) 2020-03-31 2022-11-18 百奥泰生物制药股份有限公司 用于治疗冠状病毒的抗体、融合蛋白及其应用
EP3909601A1 (de) 2020-05-11 2021-11-17 LeukoCom GmbH Neuer antikörper, der spezifisch an menschliches ceacam1/3/5 bindet, und dessen verwendung
CA3183756A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
JP2023527972A (ja) 2020-05-29 2023-07-03 アムジエン・インコーポレーテツド Ｃｄ３３及びｃｄ３に結合する二重特異性コンストラクトの有害作用軽減投与
EP4182475A2 (de) 2020-07-17 2023-05-24 Onena Medicines S.L. Antikörper gegen linksprotein
US20230287126A1 (en) 2020-08-07 2023-09-14 Bio-Thera Solutions, Ltd. Anti-pd-l1 antibody and use thereof
US20230365709A1 (en) 2020-10-08 2023-11-16 Affimed Gmbh Trispecific binders
CN116323671A (zh) 2020-11-06 2023-06-23 安进公司 具有增加的选择性的多靶向性双特异性抗原结合分子
WO2022095970A1 (zh) 2020-11-06 2022-05-12 百奥泰生物制药股份有限公司 双特异抗体及其应用
TW202225188A (zh) 2020-11-06 2022-07-01 德商安美基研究（慕尼黑）公司 與ｃｄ３結合的多肽構建體
CA3199976A1 (en) 2020-11-06 2022-05-12 Amgen Research (Munich) Gmbh Polypeptide constructs selectively binding to cldn6 and cd3
KR20230098335A (ko) 2020-11-06 2023-07-03 암젠 인크 클리핑 비율이 감소된 항원 결합 도메인
CN114685660A (zh) 2020-12-30 2022-07-01 百奥泰生物制药股份有限公司 抗cldn18.2抗体及其制备方法和应用
BR112023021224A2 (pt) 2021-04-12 2024-01-16 Acm Biolabs Pte Ltd Polimerossomas compreendendo polinucleotídeo encapsulado solúvel e lipídio ionizável, bem como métodos de produção e usos dos mesmos
CA3217180A1 (en) 2021-05-06 2022-11-10 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
WO2023007023A1 (en) 2021-07-30 2023-02-02 Affimed Gmbh Duplexbodies
WO2023051663A1 (zh) 2021-09-30 2023-04-06 百奥泰生物制药股份有限公司 抗b7-h3抗体及其应用
CA3237018A1 (en) 2021-11-03 2023-05-11 Joachim Koch Bispecific cd16a binders
CA3233696A1 (en) 2021-11-03 2023-05-11 Joachim Koch Bispecific cd16a binders
WO2023180346A1 (en) 2022-03-22 2023-09-28 Morphosys Ag Deimmunized antibodies specific for cd3
WO2023218027A1 (en) 2022-05-12 2023-11-16 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2331936C (en) * 1990-12-05 2007-07-31 Novozymes A/S Proteins with changed epitopes and methods for the production thereof
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
EP0721982A1 (de) * 1995-01-06 1996-07-17 Leuven Research & Development V.Z.W. Neue staphylokinase Derivative
AU720966B2 (en) * 1995-03-17 2000-06-22 Novo Nordisk A/S Insulin derivatives
JP2002512624A (ja) * 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法

Also Published As

Publication number Publication date
WO2000034317A3 (en) 2000-08-17
EP1051432A2 (de) 2000-11-15
CA2342967A1 (en) 2000-06-15
WO2000034317A2 (en) 2000-06-15
DE69934967T2 (de) 2007-12-06
AU776910B2 (en) 2004-09-23
CN1202128C (zh) 2005-05-18
EP1051432B1 (de) 2007-01-24
ES2278463T3 (es) 2007-08-01
ATE352559T1 (de) 2007-02-15
CN1294596A (zh) 2001-05-09
AU1667600A (en) 2000-06-26
JP2002534959A (ja) 2002-10-22

Similar Documents

Publication Publication Date Title
ATE352559T1 (de) Verfahren zur verminderung der immunogenität von proteinen
RU95115239A (ru) Аналог эритропоэтина
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
CA2290485A1 (en) Method for the production of non-immunogenic proteins
ES2174855T3 (es) Metodos diagnosticos y composiciones farmaceuticas que se basan en proteinas notch y acidos nucleicos.
DK382786D0 (da) Overfladeaktivt rekombinant-alveolarprotein
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
DE69840195D1 (de) Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1
TR200001709T2 (tr) Yeni neisseria meningitids yüzey proteini
FI900808A0 (fi) Humant mannos bindande protein.
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
HUP0100267A2 (hu) Helicobacter pylori eredetű nukleinsav- és aminosav-szekvenciák és a megfelelő nukleinsavakat vagy peptideket tartalmazó vakcina-készítmények
EP0716591A4 (de) Verfahren und Präparat zum Binden von TAU und MAP2c Proteinen
DE69233245D1 (de) Verfahren zur Herstellung von Peptiden
DE59712235D1 (de) Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe
NZ335633A (en) Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases
DE60140559D1 (de) 32144, eine humane fettsäureamid-hydrolase und deren verwendungen
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
ATE202114T1 (de) Verwendung von peptiden welche eine immunantwort bewirken zur herstellung von medikamenten zur induzierung der immunsuppression.
DK0811068T3 (da) Humane DNase I varianter
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.
TR200002611T2 (tr) Beta-lipotropin ve kullanımları
DE60041985D1 (de) Zusammensetzungen und verfahren zur erfassung von stress induzierten proteinen
DE60139153D1 (de) 14189, eine humane kinase und deren verwendungen

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: CARR, FRANCIS JOSEPH, ABERDEEN, GB

Inventor name: ADAIR, FIONA SUZANNE, ABERDEEN, GB

Inventor name: HAMILTON, ANITA ANNE, ABERDEEN, GB

Inventor name: CARTER, GRAHAM, ABERDEEN, GB

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK PATENT GMBH, 64293 DARMSTADT, DE

8339 Ceased/non-payment of the annual fee